Welcome to our dedicated page for Rigel Pharmaceuticals (New) news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals (New) stock.
Rigel Pharmaceuticals reports news on a commercial-stage biotechnology business focused on hematologic disorders and cancer. Company updates commonly cover sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), along with contract revenue from collaborations and quarterly operating results.
Recurring developments also include clinical and regulatory updates for Rigel's pipeline, including R289 in lower-risk MDS, published clinical data involving GAVRETO, licensing and collaboration activity, board appointments, equity inducement grants and other governance matters tied to its Nasdaq-listed common stock.
Rigel (Nasdaq:RIGL) entered an exclusive global license agreement with Arvinas and Pfizer for VEPPANU™ (vepdegestrant), the first FDA-approved oral PROTAC for 2L+ ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
VERITAC-2 showed median PFS 5.0 vs 2.1 months vs fulvestrant (43% risk reduction). Rigel will pay $70M upfront, $15M after transition activities, up to $320M in milestones, contribute up to $40M to development, and pay mid-teens to mid-twenties royalties. VEPPANU becomes Rigel’s fourth commercial product upon expected closing in mid-June 2026 and is listed as a Category 2A option in NCCN Breast Cancer Guidelines.
Rigel (Nasdaq: RIGL) reported Q1 2026 results: total revenues $58.8M including $54.9M net product sales, net income of $8.7M, and cash, cash equivalents and short-term investments of $146.7M as of March 31, 2026. The company reaffirmed 2026 revenue guidance of $275–$290M and expects positive net income for the year. Clinical progress includes ongoing R289 Phase 1b dose-expansion enrollment and planned Phase 2 dose selection in H2 2026.
Rigel Pharmaceuticals (Nasdaq: RIGL) will report first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss results and business updates.
Dial-in numbers are 877-407-3088 (domestic) and 201-389-0927 (international). The webcast, slides, and a replay will be available from the Investor Relations section of www.rigel.com and archived for 90 days.
Rigel is a biotechnology company focused on therapies for hematologic disorders and cancer, based in South San Francisco.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement awards under Nasdaq Listing Rule 5635(c)(4) dated April 7, 2026. The company granted 8,925 restricted stock units to six non-executive employees that vest over four years, with 25% vesting each year.
This action was approved by Rigel's Compensation Committee and issued as inducements for new employees joining the company.
Rigel (Nasdaq: RIGL) announced publication of final Phase 1/2 ARROW data for GAVRETO (pralsetinib) in RET fusion-positive NSCLC in the Journal of Clinical Oncology on March 31, 2026.
Key results: overall response rate 70% (n=259), treatment-naive ORR 78%, median OS 44.3 months, median PFS 13.1 months, intracranial ORR 53% (15 patients); safety described as manageable with three treatment-related deaths reported.
Rigel (Nasdaq: RIGL) reported Q4 2025 revenue of $69.8M and full-year 2025 revenue of $294.3M, driven by record net product sales of $65.4M in Q4 and $232.0M for the year. Net income was $268.1M in Q4 and $367.0M for 2025, largely reflecting a $245.9M non-cash deferred tax benefit.
Commercial growth, advancing R289 Phase 1b enrollment, recent clinical data releases, FDA labeling update for GAVRETO, and 2026 guidance of $275–$290M revenue support the company outlook.
Rigel (Nasdaq: RIGL) will report fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. A live conference call and webcast will follow at 4:30 p.m. ET to review results and provide a business update.
Investors can join by phone or via the Investor Relations webcast at www.rigel.com; the webcast will be archived for 90 days.
Rigel (Nasdaq: RIGL) appointed Michael P. Miller to its Board of Directors effective Feb. 3, 2026. Mr. Miller brings over four decades of commercial and leadership experience across biotechnology and pharmaceuticals, including executive commercial roles at Jazz Pharmaceuticals and Genentech and current board service at Puma Biotechnology and BioXcel Therapeutics.
The company said his commercial expertise will support Rigel's strategic plan to grow marketed medicines and evaluate in-licensing opportunities to expand its hematologic and oncology portfolio.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced the first patient enrollment in a Phase 1b/2 trial at MD Anderson testing oral or IV decitabine and venetoclax combined with REZLIDHIA (olutasidenib) for mIDH1 acute myeloid leukemia (AML) on Jan 15, 2026.
The Phase 1b portion will assess safety/tolerability and recommended Phase 2 dose; the Phase 2 will enroll 60 patients (30 newly diagnosed, 30 relapsed/refractory) to evaluate complete remission rate. REZLIDHIA is FDA‑indicated for relapsed/refractory mIDH1 AML. The release includes safety data: differentiation syndrome and hepatotoxicity incidence and management guidance.
Rigel (Nasdaq: RIGL) reported preliminary Q4 2025 total revenue of $69.8M with net product sales of $65.4M. For full-year 2025 the company expects total revenue of $294.3M and net product sales of $232.0M, driven by TAVALISSE, GAVRETO and REZLIDHIA. Cash, cash equivalents and short-term investments were approximately $154.6M at 12/31/2025. Rigel provided 2026 outlook of total revenue $275–290M, net product sales $255–265M, contract revenue $20–25M, and anticipates positive net income for 2026. Clinically, R289 Phase 1b dose-escalation showed RBC-TI of 33% (6/18) at ≥500 mg QD; dose expansion enrollment is ongoing with preliminary expansion data expected by end of 2026.